Skip to main content
Top
Published in: Medical Oncology 2/2013

01-06-2013 | Original Paper

To operate or to radiate: the added value of the maximal standardized uptake value in PET–FDG in cervical cancer patients

Authors: Itamar Netzer, Shehrban Sobeh, Zohar Keidar, Lior Lowenstein, Ofer Lavie, Rahamim Ben Yosef, Amnon Amit

Published in: Medical Oncology | Issue 2/2013

Login to get access

Abstract

Cervical cancer is one of the leading causes of death among women with gynecological malignancies. In early stages of the disease (IB-IIA), surgical treatment alone is usually the treatment of choice. However, some high-risk patients are referred for postoperative chemo-radiotherapy, leading to increased morbidity. Maximal Standardized Uptake Value (SUVmax) is a positron emission tomography–computed tomography (PET–CT)-derived semiquantitative measurement of fluorodeoxyglucose (FDG) uptake in a defined lesion and may reflect tumor aggressiveness. The purpose of this study was to determine whether preoperative high SUVmax values can be used for the selection of initial therapy, thus reducing the side effects resulting from bimodal treatment. PET–CT studies of 46 cervical cancer patients who underwent surgery were reviewed, and SUVmax data were collected. Statistical analyses were performed to determine the relationships between SUVmax values and clinical parameters, modalities of treatment, and outcomes. SUVmax was found to correlate with depth of tumor invasion (r = 0.46, p < 0.003). A statistically significant correlation was also found between SUVmax and histological grade, with the mean and variance of SUVmax significantly lower for grade one, as compared to grades two and three (mean 1.10, 11.06, and 8.88; variance 3.57, 45.60, and 29.79, respectively; p < 0.0001 and p = 0.076). A possible SUVmax cutoff value of 10.08 was identified as a potential indicator of increased risk for receiving bimodal treatment, with a sensitivity of 61.5 % and a specificity of 75.8 %. SUVmax can be used for differentiating early-stage cervical cancer patients who will need postoperative adjuvant treatment and therefore can serve as an additional modality to reduce the need for bimodal therapy in these patients.
Literature
1.
3.
go back to reference Landoni F, Maneo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350(9077):535–40.PubMedCrossRef Landoni F, Maneo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350(9077):535–40.PubMedCrossRef
4.
go back to reference Rotman M, Sedlis A, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65(1):169–76.PubMedCrossRef Rotman M, Sedlis A, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65(1):169–76.PubMedCrossRef
5.
go back to reference Nout RA, van de Poll-Franse LV, Lybeert ML, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011;29(13):1692–700.PubMedCrossRef Nout RA, van de Poll-Franse LV, Lybeert ML, et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol. 2011;29(13):1692–700.PubMedCrossRef
6.
go back to reference Kidd EA, Spencer CR, et al. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer. 2009;15(115):3548–54.CrossRef Kidd EA, Spencer CR, et al. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer. 2009;15(115):3548–54.CrossRef
7.
go back to reference Benedet JL, Bender H, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology. Int J Gynaecol Obstet. 2000;70(2):209–62.PubMedCrossRef Benedet JL, Bender H, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO committee on gynecologic oncology. Int J Gynaecol Obstet. 2000;70(2):209–62.PubMedCrossRef
8.
go back to reference Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRef Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedCrossRef
10.
go back to reference Amit A, Schink J, Reiss A, Lowenstein L. PET/CT in gynecologic cancer: present applications and future prospects–a clinician’s perspective. Obstet Gynecol Clin North Am. 2011;38(1):1–21.PubMedCrossRef Amit A, Schink J, Reiss A, Lowenstein L. PET/CT in gynecologic cancer: present applications and future prospects–a clinician’s perspective. Obstet Gynecol Clin North Am. 2011;38(1):1–21.PubMedCrossRef
11.
go back to reference Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995;32(5):1289–300.PubMedCrossRef Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995;32(5):1289–300.PubMedCrossRef
12.
go back to reference Kasibhatla M, Clough RW, Montana GS, et al. Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2006;65(2):398–403.PubMedCrossRef Kasibhatla M, Clough RW, Montana GS, et al. Predictors of severe gastrointestinal toxicity after external beam radiotherapy and interstitial brachytherapy for advanced or recurrent gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2006;65(2):398–403.PubMedCrossRef
13.
go back to reference Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma—a prospective randomized study. Int J Radiat Oncol Biol Phys. 2012;82(3):1249–55.PubMedCrossRef Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma—a prospective randomized study. Int J Radiat Oncol Biol Phys. 2012;82(3):1249–55.PubMedCrossRef
14.
go back to reference Perez CA, Breaux S, Bedwinek JM, et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications. Cancer. 1984;54(2):235–46.PubMedCrossRef Perez CA, Breaux S, Bedwinek JM, et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix. II. Analysis of complications. Cancer. 1984;54(2):235–46.PubMedCrossRef
15.
go back to reference Grigsby PW. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging. 2008;8:146–55.PubMedCrossRef Grigsby PW. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging. 2008;8:146–55.PubMedCrossRef
16.
go back to reference Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426–35.PubMedCrossRef Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38(3):426–35.PubMedCrossRef
17.
go back to reference Ikenaga N, Otomo N, Toyofuku A, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg. 2007;73(11):1151–7.PubMed Ikenaga N, Otomo N, Toyofuku A, et al. Standardized uptake values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg. 2007;73(11):1151–7.PubMed
18.
go back to reference Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG–PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34(12):1915–24.PubMedCrossRef Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG–PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007;34(12):1915–24.PubMedCrossRef
19.
go back to reference Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96(2):166–70.PubMedCrossRef Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N. Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg. 2009;96(2):166–70.PubMedCrossRef
20.
go back to reference Casali C, Cucca M, Rossi G, et al. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected non-small cell lung carcinoma. Lung cancer. 2010;69(2):187–93.PubMedCrossRef Casali C, Cucca M, Rossi G, et al. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected non-small cell lung carcinoma. Lung cancer. 2010;69(2):187–93.PubMedCrossRef
21.
go back to reference Yen TC, See LC, Lai CH, et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging. 2008;35(3):493–501.PubMedCrossRef Yen TC, See LC, Lai CH, et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging. 2008;35(3):493–501.PubMedCrossRef
22.
go back to reference Chung HH, Nam BH, Kim JW, et al. Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. Eur J Nucl Med Mol Imaging. 2010;37(8):1467–73.PubMedCrossRef Chung HH, Nam BH, Kim JW, et al. Preoperative [18F]FDG PET/CT maximum standardized uptake value predicts recurrence of uterine cervical cancer. Eur J Nucl Med Mol Imaging. 2010;37(8):1467–73.PubMedCrossRef
23.
go back to reference Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110(8):1738–44.PubMedCrossRef Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110(8):1738–44.PubMedCrossRef
24.
go back to reference Xue F, Lin LL, Dehdashti F, Miller TR, Siegel BA, Grigsby PW. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol. 2006;101(1):147–51.PubMedCrossRef Xue F, Lin LL, Dehdashti F, Miller TR, Siegel BA, Grigsby PW. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol. 2006;101(1):147–51.PubMedCrossRef
Metadata
Title
To operate or to radiate: the added value of the maximal standardized uptake value in PET–FDG in cervical cancer patients
Authors
Itamar Netzer
Shehrban Sobeh
Zohar Keidar
Lior Lowenstein
Ofer Lavie
Rahamim Ben Yosef
Amnon Amit
Publication date
01-06-2013
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2013
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0558-z

Other articles of this Issue 2/2013

Medical Oncology 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.